Lilly withdraws application for Cymbalta for additional indication of chronic pain
Tuesday, December 02, 2008 13:00 IST Indianapolis, Indiana
Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the US Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain.